Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.57, Fidelity Earnings reports. The company had revenue of $29.04 million during the quarter.
Shares of NASDAQ:XNCR opened at $40.33 on Wednesday. The company has a market cap of $2.12 billion, a P/E ratio of -38.41 and a beta of 1.73. Xencor has a 1-year low of $19.50 and a 1-year high of $48.38.
XNCR has been the subject of several recent analyst reports. BTIG Research initiated coverage on shares of Xencor in a report on Monday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. BidaskClub upgraded shares of Xencor from a “hold” rating to a “buy” rating in a report on Thursday, September 20th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Xencor in a report on Monday, October 8th. Cantor Fitzgerald set a $40.00 price objective on shares of Xencor and gave the company a “buy” rating in a report on Tuesday. Finally, Piper Jaffray Companies restated an “overweight” rating on shares of Xencor in a report on Tuesday, August 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $41.13.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.